<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349242</url>
  </required_header>
  <id_info>
    <org_study_id>MGT011</org_study_id>
    <nct_id>NCT03349242</nct_id>
  </id_info>
  <brief_title>Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)</brief_title>
  <official_title>Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MeiraGTx UK II Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MeiraGTx UK II Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rod-cone dystrophies (often referred to as retinitis pigmentosa (RP)) are a clinically&#xD;
      and genetically heterogeneous group of disorders in which there is progressive loss of rod&#xD;
      and later cone photoreceptor function leading to severe visual impairment. RP usually occurs&#xD;
      as an isolated retinal disorder, but it may also be seen in association with systemic&#xD;
      abnormalities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      X-linked Retinitis Pigmentosa (XLRP) is a severe form of RP with early onset of nyctalopia&#xD;
      and progression to legal blindness by the 3rd to 4th decade. Most affected males show&#xD;
      symptomatic night blindness before the age of 10 years, are often myopic and show fundus&#xD;
      abnormalities and ERG changes in early childhood. Examination of close female relatives is&#xD;
      helpful in the absence of a family history, as the recognition of the XL carrier state will&#xD;
      confirm the diagnosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of retinal structure and function to assess disease progression</measure>
    <time_frame>6 years</time_frame>
    <description>Retinal structure will be measured using Adaptive optics and SD-OCT and Fundal autofluorescence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Sensitivity</measure>
    <time_frame>6 years</time_frame>
    <description>To be assessed by Microperimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Structural detailed phenotyping</measure>
    <time_frame>6 years</time_frame>
    <description>Retinal Structure measured by Adaptive Optics (</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fundus Autofluorescence</measure>
    <time_frame>6 years</time_frame>
    <description>Presence or Absence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Fields testing</measure>
    <time_frame>6 years</time_frame>
    <description>Assessment of Visual Fields with analysis of hill vision by perimetry</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with RPGR-associated retinal dystrophy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males &amp; Females aged 5 years or older&#xD;
&#xD;
          -  Have RPGR-associated retinal dystrophy&#xD;
&#xD;
          -  Are able to give informed consent or assent, with the guidance of their&#xD;
             parent/guardian where appropriate&#xD;
&#xD;
          -  Are able to undertake age-appropriate clinical assessments as specified in the&#xD;
             protocol&#xD;
&#xD;
          -  Have genetic mutation within the RPGR gene confirmed by an accredited lab or research&#xD;
             lab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are unable or unwilling to undertake consent or clinical testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Michaelides, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL/Moorfields</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MeiraGTx UK II Ltd</last_name>
    <phone>+44 (0) 20 3866 4320</phone>
    <email>ocularinfo@meiragtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shiley Eye Institute - UCSD</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iliana Molina</last_name>
      <phone>858-822-2585</phone>
    </contact>
    <investigator>
      <last_name>Shyamanga Borooah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Eye Centre</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Tribe</last_name>
      <phone>404-778-5629</phone>
    </contact>
    <investigator>
      <last_name>Nieraj Jain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Wen</last_name>
      <phone>617-573-3780</phone>
      <email>OphthalmologyClinicalResearch@meei.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Racheal Huckfeldt, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrienne Chen</last_name>
      <phone>734-232-9167</phone>
      <email>KelloggResearch@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Thiran Jayasundera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Eye Centre</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Miller</last_name>
      <phone>412-647-3928</phone>
    </contact>
    <investigator>
      <last_name>Mahmood Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 0A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaishnavi Batmanabane</last_name>
    </contact>
    <investigator>
      <last_name>Elise Heon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oritsemiyemi Omatsuli</last_name>
      <phone>020 7253 3411</phone>
    </contact>
    <investigator>
      <last_name>Michel Michaelides</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

